Condition: Primary Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Sponsor: Ajax Therapeutics, Inc.
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
This description comes directly from the study's public registry record.
David Steensma, M.D. · 917-410-7250 · david@ajaxtherapeutics.com
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute | Palo Alto, California, United States | Recruiting |
| Moffitt Cancer Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06343805